Morten Opstad Reveals Voting Rights Ahead of Key Meeting
Voting Rights Disclosure of IDEX Biometrics Chair
On a recent date, Morten Opstad, the chair of IDEX Biometrics, provided a detailed account of his voting rights in relation to the upcoming extraordinary general meeting. This meeting is an essential event for all stakeholders, showcasing the active involvement of board members in the company’s governance.
Breakdown of Voting Rights
As of the latest conclusion of business, Opstad disclosed that he has voting rights across several categories:
- He is authorized to vote according to instructions for 15,705,542 shares, representing 4.7% of the company’s total share capital and votes.
- Additionally, a proxy has been assigned for 50,982,106 shares, amounting to 15.1% of the total.
- Furthermore, 1,474,002 shares, accounting for 0.4%, are held by Opstad and his immediate relations.
- When combined, these figures indicate that Opstad and close relations collectively hold 68,161,650 shares, which constitutes 20.2% of the total voting rights.
Significance of Voting Rights
Understanding the voting rights held by key figures such as Morten Opstad is crucial for investors and market observers. The ability to influence strategic decisions significantly impacts stockholder values and the trajectory of IDEX Biometrics. As a leading player in fingerprint biometrics, Opstad's voting power plays a vital role in shaping the company’s future.
About IDEX Biometrics
IDEX Biometrics ASA, listed on the Oslo stock exchange under ticker IDEX, stands at the forefront of fingerprint biometrics technology. Their innovations extend to various sectors, including payment solutions, access control, and digital identity verification. By providing secure and user-friendly authentication solutions built on proprietary sensor technology and software, IDEX Biometrics enhances consumer experiences while securing sensitive information.
Contact Information
For any inquiries related to IDEX Biometrics, individuals can reach out to Marianne Bøe, the Head of Investor Relations, at +47 9180 0186 or through email at marianne.boe@idexbiometrics.com. Engaging with the investor relations team ensures that stakeholders remain informed and connected with the company's ongoing developments.
Frequently Asked Questions
What are the implications of the voting rights held by Morten Opstad?
The voting rights enable him to significantly influence the company's decisions, affecting strategies and shareholder interests.
How many shares does Morten Opstad control?
Opstad controls a total of 68,161,650 shares, which is 20.2% of the total voting rights.
What is the role of IDEX Biometrics in the technology sector?
IDEX Biometrics is a leader in fingerprint biometrics, offering secure authentication solutions for payments and digital identities.
How can I contact IDEX Biometrics for more information?
You can contact Marianne Bøe, Head of Investor Relations, at +47 9180 0186 or via email.
What products does IDEX Biometrics specialize in?
IDEX specializes in biometric solutions targeting card-based applications, enhancing security and user convenience in various sectors.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.